Carmat (ALCAR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Carmat (ALCAR) has a cash flow conversion efficiency ratio of 0.344x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-17.58 Million ≈ $-20.56 Million USD) by net assets (€-51.13 Million ≈ $-59.78 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ALCAR cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Carmat - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Carmat's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Carmat Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Carmat ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FIRST LITHIUM MINERALS
F:X28
|
-0.160x |
|
Lifecare AS
OL:LIFE
|
3.325x |
|
Daekyo Co Ltd
KO:019685
|
0.035x |
|
Loyal Solutions AS
ST:LOYAL
|
0.017x |
|
Henderson Far East Income Ltd
LSE:HFEL
|
0.025x |
|
Henderson Smaller Cos Inv Tst
LSE:HSL
|
0.009x |
|
Charan Insurance Public Company Limited
BK:CHARAN
|
0.003x |
|
GENINCODE PLC LS -01
F:9PL
|
N/A |
Annual Cash Flow Conversion Efficiency for Carmat (2010–2024)
The table below shows the annual cash flow conversion efficiency of Carmat from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see Carmat (ALCAR) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-51.13 Million ≈ $-59.78 Million |
€-43.31 Million ≈ $-50.64 Million |
0.847x | -30.68% |
| 2023-12-31 | €-43.76 Million ≈ $-51.16 Million |
€-53.48 Million ≈ $-62.52 Million |
1.222x | +104.05% |
| 2022-12-31 | €1.80 Million ≈ $2.11 Million |
€-54.38 Million ≈ $-63.57 Million |
-30.175x | -788.21% |
| 2021-12-31 | €-13.72 Million ≈ $-16.04 Million |
€-60.17 Million ≈ $-70.34 Million |
4.385x | +179.66% |
| 2020-12-31 | €7.82 Million ≈ $9.14 Million |
€-43.03 Million ≈ $-50.31 Million |
-5.504x | -232.89% |
| 2019-12-31 | €24.34 Million ≈ $28.46 Million |
€-40.24 Million ≈ $-47.05 Million |
-1.653x | +11.04% |
| 2018-12-31 | €20.54 Million ≈ $24.01 Million |
€-38.17 Million ≈ $-44.63 Million |
-1.859x | -337.96% |
| 2017-12-31 | €57.21 Million ≈ $66.88 Million |
€-24.28 Million ≈ $-28.38 Million |
-0.424x | +42.37% |
| 2016-12-31 | €28.89 Million ≈ $33.77 Million |
€-21.27 Million ≈ $-24.87 Million |
-0.736x | +93.99% |
| 2015-12-31 | €1.40 Million ≈ $1.64 Million |
€-17.19 Million ≈ $-20.09 Million |
-12.248x | -407.32% |
| 2014-12-31 | €7.76 Million ≈ $9.08 Million |
€-18.75 Million ≈ $-21.92 Million |
-2.414x | -81.08% |
| 2013-12-31 | €7.23 Million ≈ $8.45 Million |
€-9.64 Million ≈ $-11.27 Million |
-1.333x | +26.17% |
| 2012-12-31 | €9.94 Million ≈ $11.62 Million |
€-17.95 Million ≈ $-20.99 Million |
-1.806x | -400.34% |
| 2011-12-31 | €26.89 Million ≈ $31.44 Million |
€-9.71 Million ≈ $-11.35 Million |
-0.361x | +19.55% |
| 2010-12-31 | €15.49 Million ≈ $18.11 Million |
€-6.95 Million ≈ $-8.13 Million |
-0.449x | -- |
About Carmat
Carmat SA designs and develops total artificial heart for patients with advanced heart failure in France and internationally. The company offers Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France.